Navigation Links
Warner Chilcott Reports the Death of Its Director James Andress
Date:3/14/2008

ST. DAVID'S, Bermuda, March 14 /PRNewswire-FirstCall/ -- It is with a profound sense of loss that Warner Chilcott Limited (Nasdaq: WCRX) reports today that Mr. James G. Andress, a director of the Company, died on Tuesday, March 11, 2008.

Roger Boissonneault, Chief Executive Officer, President and Director of Warner Chilcott Limited, issued the following statement:

"We report the loss of Jim Andress with great sadness. Jim was instrumental in the development of this Company. His thoughtful guidance and counsel will be sorely missed. Our deepest sympathies go out to Jim's family."

Mr. Andress was appointed to the Company's board of directors in August of 2006, and at the time of his passing he also served as the co-chairman of the audit committee of the board of directors. Mr. Andress was a former Chairman of the Pharmaceuticals Group, Beecham Group, plc, former Chairman, Healthcare Products and Services of SmithKline Beecham, plc and former President and Chief Operating Officer of Sterling Drug, Inc. From 1996 to 2000, Mr. Andress served as Chairman and Chief Executive Officer of Warner Chilcott PLC (acquired by the Company's predecessor in September 2000). Mr. Andress also served on the board of directors of Sepracor, Inc., XOMA Ltd. and Allstate Insurance Company.

About Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G

Read more on http://www.warnerchilcott.com.


'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
2. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selectorâ„¢ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):